Literature DB >> 33158637

PNPT1 mutations may cause Aicardi-Goutières-Syndrome.

Daniel Bamborschke1, Mona Kreutzer1, Anne Koy2, Friederike Koerber3, Nadja Lucas4, Christoph Huenseler2, Peter Herkenrath2, Min Ae Lee-Kirsch4, Sebahattin Cirak5.   

Abstract

BACKGROUND: Aicardi-Goutières syndrome (AGS) is a clinically and genetically heterogenous autoinflammatory disorder caused by constitutive activation of the type I interferon axis. It has been associated with the genes TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, IFIH1. The clinical diagnosis of AGS is usually made in the context of early-onset encephalopathy in combination with basal ganglia calcification or white matter abnormalities on cranial MRI and laboratory prove of interferon I activation. CASE
PRESENTATION: We report a patient with early-onset encephalopathy, severe neurodevelopmental regression, progressive secondary microcephaly, epilepsy, movement disorder, and white matter hyperintensities on T2 weighted MRI images. Via whole-exome sequencing, we identified a novel homozygous missense variant (c.1399C > T, p.Pro467Ser) in PNPT1 (NM_033109). Longitudinal assessment of the interferon signature showed a massively elevated interferon score and chronic type I interferon-mediated autoinflammation.
CONCLUSION: Bi-allelic mutations in PNPT1 have been reported in early-onset encephalopathy. Insufficient nuclear RNA import into mitochondria with consecutive disruption of the respiratory chain was proposed as the main underlying pathomechanism. Recent studies have shown that PNPT1 deficiency causes an accumulation of double-stranded mtRNAs in the cytoplasm, leading to aberrant type I interferon activation, however, longitudinal assessment has been lacking. Here, we present a case of AGS with continuously elevated type I interferon signature with a novel likely-pathogenic homozygous PNTP1 variant. We highlight the clinical value of assessing the interferon signature in children with encephalopathy of unknown origin and suggest all patients presenting with a phenotype of AGS should be screened for mutations in PNPT1.
Copyright © 2020 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aicardi-Goutières-Syndrome; Early-onset encephalopathy; Interferon signature; PNPT1; Type I interferonopathy

Year:  2020        PMID: 33158637     DOI: 10.1016/j.braindev.2020.10.005

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  3 in total

1.  Analysis of clinical characteristics of children with Aicardi-Goutieres syndrome in China.

Authors:  Wei Wang; Wei Wang; Ting-Yan He; Li-Ping Zou; Wen-Dao Li; Zhong-Xun Yu; Ming-Sheng Ma; Jun Yang; Hong-Mei Song
Journal:  World J Pediatr       Date:  2022-05-12       Impact factor: 9.186

2.  SP1 and NFY Regulate the Expression of PNPT1, a Gene Encoding a Mitochondrial Protein Involved in Cancer.

Authors:  Ignacio Ventura; Fernando Revert; Francisco Revert-Ros; Lucía Gómez-Tatay; Jesús A Prieto-Ruiz; José Miguel Hernández-Andreu
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

3.  Increased presence of nuclear DNAJA3 and upregulation of cytosolic STAT1 and of nucleic acid sensors trigger innate immunity in the ClpP-null mouse.

Authors:  Antonia Maletzko; Jana Key; Ilka Wittig; Suzana Gispert; Gabriele Koepf; Júlia Canet-Pons; Sylvia Torres-Odio; A Phillip West; Georg Auburger
Journal:  Neurogenetics       Date:  2021-08-03       Impact factor: 2.660

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.